neuroClues, a French-Belgian MedTech startup empowering clinicians with biomarkers permitting them to determine neurological issues years earlier than seen signs, has raised a €10 million Collection A, together with extra non-dilutive funding, bringing the whole capital raised by the corporate to €25 million.
The spherical is led by Teampact Ventures, White Fund and the EIC Fund (European Innovation Council), with participation from current traders (InvestBW, Leansquare, Wallonie Entreprendre) and the assist of Olivier Legrain, Chairman of the Board and CEO of IBA.
“This Collection A validates our expertise and our skill to execute. CE certification in 5 months. First industrial deployments inside weeks. A normative database undertaking with 25,000 members. Right this moment, we give clinicians an goal strategy to assess neurological anomalies. As our dataset grows, our resolution will assist them determine particular pathologies earlier and extra exactly than ever earlier than. That’s the place we’re headed,” mentioned Antoine Pouppez, CEO, neuroClues.
Powered by P3Lab and based in 2020 by Antoine Pouppez, Pierre Daye, and Pierre Pouget, neuroClues develops and commercialises a compact, non-invasive, CE-marked (Class IIa) medical gadget that data and analyses eye actions to extract goal and reproducible biomarkers, supporting clinicians within the prognosis and monitoring of neurological issues in medical observe.
In response to the corporate, neurodegenerative illnesses are more and more prevalent, affecting 1 in 3 individuals whereas remaining tough to diagnose. neuroClues warns that the variety of individuals affected by Parkinson’s illness worldwide is predicted to double to 13 million by 2040. It additionally states that round one in 5 sufferers continues to be misdiagnosed, and by the point the illness is appropriately recognized, irreversible mind injury has already occurred, resulting in a lack of 65% of affected neurons.
The startup states that clinicians nonetheless rely totally on medical observations with no quantitative output, such because the “observe my finger” take a look at, and superior applied sciences resembling imaging are costly, not extensively accessible and sometimes fail to detect abnormalities at early illness levels.
neuroClues has developed a transportable, CE-marked class IIa medical gadget that shortly extracts neurological biomarkers from eye actions. A compact system captures high-speed infrared pictures of every eye because the affected person performs easy visible duties. Proprietary AI algorithms then compute goal, reproducible biomarkers.
“Its constraint-free, plug-and-play design with instant integration within the medical workflow brings ends in minutes (distant interpretation potential), offering essential clues inside the session time, not months after,” talked about the corporate within the press launch.
neuroClues assists clinicians in objectively evaluating neurological anomalies, changing the subjective “observe my finger” take a look at with quantified, reproducible information.
Because the platform gathers medical information on a big scale, it goals to assist the identification of particular situations: differentiating Parkinson’s from atypical Parkinsonisms, highlighting early indicators of Alzheimer’s, and detecting concussion-related impairments. Every gadget deployed makes the platform extra clever.
The corporate obtained its CE certification in January 2025. It reported that inside months, over 30 units had been deployed throughout France, Belgium, Italy, Germany, Switzerland, the Netherlands, and the UK, in college hospitals, non-public neurology practices, and analysis centres. The corporate additionally studies rising inbound demand from clinicians who’ve seen the gadget at congresses or referenced by friends.
In response to the corporate, this industrial traction is supported by a number of medical and institutional milestones. These embrace integration into the Paris Mind Institute’s (ICM) medical cohorts, such because the Iceberg examine on Parkinson’s illness, and choice for the mega-cohort (25,000 members), which is able to develop the primary large-scale normative database of oculomotor biomarkers.
The corporate additionally states it was chosen by Bpifrance’s Nationwide Prevention Accelerator, supporting the commercialisation with devoted help. Moreover, it was a part of an official French presidential delegation to India, fostering strategic partnerships with main establishments resembling AIIMS.
neuroClues has appointed Bart Stulens, former VP of Neuromodulation EMEA at Medtronic, as Chief Industrial Officer. The corporate is actively increasing its industrial crew throughout Europe, with recruitment underway in France and distributor agreements both signed or beneath dialogue within the EMEA area.
It has additionally opened a restricted tranche of as much as €1.5 million on LITA, the European influence funding platform, enabling residents and particular person traders to take part instantly on this spherical beneath the identical phrases as institutional traders.
